

Significance


- Prenatal substance exposure can have negative effects on fetal development and infant health.
- Fetal Alcohol Spectrum Disorder (FASDs) can result in physical and developmental problems.
- Prematurity, fetal withdrawal, and neonatal abstinence syndrome (NAS) are established effects of substance misuse during pregnancy.



Clinical Presentation and Management

- Onset: 12-24 hrs (heroin), 48-72 hrs (methadone, buprenorphine) up to 5-7 days
- Dysregulation leading to:
 - o CNS hyperirritability- crying, inconsolable, tremor, poor sleep
 - o GI dysfunction-feeding problems, vomiting, watery stool
 - o Respiratory symptoms-tachypnea, nasal flaring
 - o Autonomic instability- fever, yawning, mottling
- Assessment- repeated evaluation and scoring every 3-4 hours using modified Finnegan NAS score
- Non-pharmacologic interventions: comforting measures, environmental controls, maternal support
- Pharmacologic treatment (50-60%): morphine, methadone or buprenorphine





Research Question

This study aimed to determine the prevalence of antepartum maternal substance use disorder (SUD) and the incidence of NAS among American Indians/Alaska Natives (AI/AN) compared to Non-Hispanic Whites (NHW) with hospital deliveries in Washington State.





Methods



Data Source


- Washington State Comprehensive Hospital Abstract Reporting System (CHARS), 2011 – 2014
- Collects data on diagnoses, procedures, costs & payers for all inpatient discharge in community hospitals
 - Includes most (if not all) hospitalizations for AI/AN patient
 - No Indian Health Service (IHS) hospital in the Northwest tribal/urban AI/AN patients in WA must obtain inpatient care at community hospitals



AI/AN Racial Misclassification

- Challenges with race/ethnicity data quality: AI/AN are misclassified in surveillance and administrative datasets more frequently than other race/ethnicities
- Misclassification results in underestimated morbidity and mortality for AI/AN






Measures

• Identified documented substance use disorders through the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis and procedure codes.








Results




Results

- A total of 309,285 hospital deliveries in WA 2011 2014
- There were 2,077 deliveries with maternal substance use disorders
- We identified 220 AI/AN (4.0%) and 1,338 NHW deliveries (1.0%) with neonatal abstinence syndrome









Discussion



Discussion

- The results demonstrate the increasing prevalence of maternal SUD resulting in drug-exposed births in Washington.
- These findings are similar to the national trends.



Implications

- There is an urgent need to address the high rates of AI/AN maternal SUD
- Underscore the need for sustained support for infants born with NAS





Implications (Cont'd)

- The results suggest the potential benefits of culturally-centered programs for AI/AN women who use substances during pregnancy
- Integrated prenatal care and substance use treatment may deliver benefits for both mothers and neonates throughout the perinatal period.



Limitations

- Northwest Tribal Registry under-represents urban AI/AN who don't use Indian health clinics and those with private insurance
 - Includes 75-80% of AI/AN population in the Pacific Northwest
- Data on residents seeking care across state lines may not be counted in their home state



Acknowledgements

Thank you to:

The Tribes of Washington, patients, and families

WA Department of Health

WA Associations of Hospitals and Health Systems

This project was produced with funding support from Cooperative Agreement Number NU58DP006385-01, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services, or Indian Health Service





Chiao-Wen Lan, PhD, MPH Epidemiologist chiaowenlan@npaihb.org CAPT Thomas Weiser, MD, MPH Medical Epidemiologist tweiser@npaihb.org

www.npaihb.org/idea-nw

